1. Scrip
  2. >>New Products

Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

 
• By Jessica Merrill

The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch. 

FDA approved background, 3D rendering, blue street sign
Lilly will launch the RET inhibitor despite coronavirus-related limitations

Eli Lilly & Co. will immediately make Retevmo (selpercatinib) available to patients after securing US Food and Drug Administration approval on 8 May for the RET inhibitor in certain cancers driven by rearranged during transfusion (RET) alterations. Lilly Oncology president Anne White said in an interview that given the critical nature of the treatment, the company will launch the drug immediately despite the challenging commercial dynamics caused by the COVID-19 pandemic.

Retevmo was approved by FDA for adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced metastatic RET-mutant medullary thyroid cancer (MTC) in patients 12 and older, and for patients age 12 and older with RET fusion-positive thyroid cancer that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.